𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance

✍ Scribed by Nao Kurashige; Kazuyoshi Ohkawa; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Tsugiko Oze; Shinichi Kiso; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Yoshinori Doi; Akira Yamada; Kazuto Fukuda; Masahide Oshita; Eiji Mita; Hiroyuki Fukui; Toshihiko Nagase; Harumasa Yoshihara; Yasuharu Imai; Michio Kato; Takeshi Kashihara; Norio Hayashi


Book ID
106180503
Publisher
Springer Japan
Year
2009
Tongue
English
Weight
239 KB
Volume
44
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Efficacy of entecavir in patients with c
✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 287 KB πŸ‘ 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/

Efficacy of adefovir add-on lamivudine r
✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45